CL2021000296A1 - Inhibidores tipo indol y azaindol de enzimas pad. - Google Patents
Inhibidores tipo indol y azaindol de enzimas pad.Info
- Publication number
- CL2021000296A1 CL2021000296A1 CL2021000296A CL2021000296A CL2021000296A1 CL 2021000296 A1 CL2021000296 A1 CL 2021000296A1 CL 2021000296 A CL2021000296 A CL 2021000296A CL 2021000296 A CL2021000296 A CL 2021000296A CL 2021000296 A1 CL2021000296 A1 CL 2021000296A1
- Authority
- CL
- Chile
- Prior art keywords
- indole
- inhibitors
- pad enzymes
- azaindole
- azaindole inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula (I) útiles como inhibidores de PAD4, composiciones de los mismos y métodos para tratar trastornos relacionados con PAD4., (I) en donde cada uno de Anillo A, L, Q, R1, R2, R3, R4, R7, y R8 junto con otras variables son como se definen en la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862715850P | 2018-08-08 | 2018-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000296A1 true CL2021000296A1 (es) | 2021-06-25 |
Family
ID=67766306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000296A CL2021000296A1 (es) | 2018-08-08 | 2021-02-03 | Inhibidores tipo indol y azaindol de enzimas pad. |
Country Status (18)
Country | Link |
---|---|
US (1) | US11524959B1 (es) |
EP (1) | EP3833440A1 (es) |
JP (1) | JP2021534108A (es) |
KR (1) | KR20210042934A (es) |
CN (1) | CN112805067A (es) |
AR (1) | AR115920A1 (es) |
AU (1) | AU2019319835A1 (es) |
BR (1) | BR112021002091A2 (es) |
CA (1) | CA3108791A1 (es) |
CL (1) | CL2021000296A1 (es) |
CO (1) | CO2021001217A2 (es) |
EA (1) | EA202190462A1 (es) |
IL (1) | IL280650A (es) |
MX (1) | MX2021001565A (es) |
PE (1) | PE20211068A1 (es) |
SG (1) | SG11202101174RA (es) |
TW (1) | TW202019415A (es) |
WO (1) | WO2020033520A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3833671B1 (en) | 2018-08-08 | 2022-08-24 | Bristol-Myers Squibb Company | Substituted thienopyrroles as pad4 inhibitors |
US11524959B1 (en) | 2018-08-08 | 2022-12-13 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
CR20220550A (es) | 2020-04-30 | 2022-12-15 | Gilead Sciences Inc | Inhibidores macrocíclicos de las peptidilarginina deiminasas |
CN111943947B (zh) * | 2020-07-24 | 2021-04-30 | 重庆文理学院 | 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用 |
TW202233174A (zh) * | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
US11878965B2 (en) | 2020-12-22 | 2024-01-23 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2609126T3 (es) * | 2012-07-26 | 2017-04-18 | Glaxo Group Limited | 2-(Azaindol-2-il)benzimidazoles como inhibidores de PAD4 |
CA3199601A1 (en) * | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
AR107032A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
RU2747431C2 (ru) | 2015-12-22 | 2021-05-05 | Кансера Аб | Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих |
KR20180110160A (ko) | 2016-02-23 | 2018-10-08 | 패들락 테라퓨틱스, 인코포레이티드 | Pad4의 헤테로아릴 억제제 |
CN109790162B (zh) | 2016-07-27 | 2022-06-28 | 帕德罗科治疗公司 | Pad4的共价抑制剂 |
JP7118951B2 (ja) | 2016-09-12 | 2022-08-16 | パドロック・セラピューティクス・インコーポレイテッド | Pad4のヘテロアリール阻害剤 |
WO2019001572A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
IL272667B (en) | 2017-10-18 | 2022-09-01 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
US20220348562A1 (en) | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
EP3833671B1 (en) | 2018-08-08 | 2022-08-24 | Bristol-Myers Squibb Company | Substituted thienopyrroles as pad4 inhibitors |
AU2019318415A1 (en) | 2018-08-08 | 2021-03-25 | Bristol-Myers Squibb Company | Substituted benzimidazoles as PAD4 inhibitors |
US11524959B1 (en) | 2018-08-08 | 2022-12-13 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
-
2019
- 2019-08-07 US US17/265,842 patent/US11524959B1/en active Active
- 2019-08-07 EA EA202190462A patent/EA202190462A1/ru unknown
- 2019-08-07 CN CN201980064963.9A patent/CN112805067A/zh active Pending
- 2019-08-07 KR KR1020217006477A patent/KR20210042934A/ko active Search and Examination
- 2019-08-07 AU AU2019319835A patent/AU2019319835A1/en not_active Abandoned
- 2019-08-07 SG SG11202101174RA patent/SG11202101174RA/en unknown
- 2019-08-07 WO PCT/US2019/045466 patent/WO2020033520A1/en unknown
- 2019-08-07 EP EP19759141.5A patent/EP3833440A1/en active Pending
- 2019-08-07 AR ARP190102237A patent/AR115920A1/es unknown
- 2019-08-07 CA CA3108791A patent/CA3108791A1/en active Pending
- 2019-08-07 BR BR112021002091-8A patent/BR112021002091A2/pt not_active Application Discontinuation
- 2019-08-07 MX MX2021001565A patent/MX2021001565A/es unknown
- 2019-08-07 TW TW108128155A patent/TW202019415A/zh unknown
- 2019-08-07 JP JP2021506683A patent/JP2021534108A/ja active Pending
- 2019-08-07 PE PE2021000171A patent/PE20211068A1/es unknown
-
2021
- 2021-02-03 CO CONC2021/0001217A patent/CO2021001217A2/es unknown
- 2021-02-03 CL CL2021000296A patent/CL2021000296A1/es unknown
- 2021-02-04 IL IL280650A patent/IL280650A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019319835A1 (en) | 2021-03-25 |
CA3108791A1 (en) | 2020-02-13 |
EA202190462A1 (ru) | 2021-06-03 |
CO2021001217A2 (es) | 2021-02-26 |
KR20210042934A (ko) | 2021-04-20 |
BR112021002091A2 (pt) | 2021-05-04 |
PE20211068A1 (es) | 2021-06-09 |
TW202019415A (zh) | 2020-06-01 |
SG11202101174RA (en) | 2021-03-30 |
CN112805067A (zh) | 2021-05-14 |
IL280650A (en) | 2021-03-25 |
WO2020033520A1 (en) | 2020-02-13 |
US11524959B1 (en) | 2022-12-13 |
AR115920A1 (es) | 2021-03-10 |
MX2021001565A (es) | 2021-04-19 |
EP3833440A1 (en) | 2021-06-16 |
JP2021534108A (ja) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021001217A2 (es) | Inhibidores tipo indol y azaindol de enzimas pad | |
CO2019011584A2 (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos | |
UY37310A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
UY37537A (es) | Derivados de pirazol como inhibidores malt1 | |
CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
PE20180117A1 (es) | Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer | |
CO2020002959A2 (es) | Moduladores de piruvato quinasas y uso de los mismos | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
AR099023A1 (es) | Pirazolil-heteroarilamidas como agentes plaguicidas | |
PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
EA202191519A1 (ru) | Модуляторы trex1 | |
UY36263A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso | |
MX2017013877A (es) | Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
ECSP21044843A (es) | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina | |
PE20191032A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos | |
CO2019004164A2 (es) | Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa | |
BR112014030474A2 (pt) | novos compostos bicíclicos de tiofenilamida | |
AR100821A1 (es) | Pirazolil-triazolil-piridinas como agentes plaguicidas | |
CR20160180A (es) | Compuestos heterocíclicos de n-acilimino | |
UY35685A (es) | Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso |